Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables: 2009-2024

Historic Receivables for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $28.9 million.

  • Gyre Therapeutics' Receivables rose 28.61% to $26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.6 million, marking a year-over-year increase of 41.78%. This contributed to the annual value of $28.9 million for FY2024, which is 85.98% up from last year.
  • Per Gyre Therapeutics' latest filing, its Receivables stood at $28.9 million for FY2024, which was up 85.98% from $15.6 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Receivables ranged from a high of $28.9 million in FY2024 and a low of $1.8 million during FY2021.
  • Over the past 3 years, Gyre Therapeutics' median Receivables value was $17.1 million (recorded in 2022), while the average stood at $20.5 million.
  • In the last 5 years, Gyre Therapeutics' Receivables tumbled by 45.13% in 2021 and then surged by 842.57% in 2022.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Receivables stood at $3.3 million in 2020, then tumbled by 45.13% to $1.8 million in 2021, then surged by 842.57% to $17.1 million in 2022, then dropped by 9.24% to $15.6 million in 2023, then soared by 85.98% to $28.9 million in 2024.